Essex Bio-Technology appoints Dr. Xue Qi as Chief Scientific Officer for its R&D Centre in USA
2018.04.10 Download
Hong Kong, 9 April 2018
ESSEX BIO-TECHNOLOGY LIMITED (“EssexBio” or the “Group”-Stock code: 1061) is pleased to announce its appointment of Dr. Xue Qi (MD. PhD.) as Chief Scientific Officer of EssexBio and Vice President (Science of Technology) of Essex Bio-Investment Limited. Dr. Xue Qi will lead the R&D Centre in USA, which is being set-up, for R&D projects, primarily in oncology, ophthalmology & dermatology.
Dr. Xue is a well-known global medical science expert in anticancer drug discovery and development. He is highly experienced in tumor microenvironment, immune-oncology and angiogenesis assessment. In June 2014, Dr. Xue obtained his Clinical Research Scholar Certificate from Harvard Medical School in the USA. Dr. Xue graduated from Gunma University in Japan with a PhD degree in Pathology in 2001.
Prior to joining the Group, Dr. Xue has worked for Eli Lilly as one of the key members in its R&D team. He also served as a postdoctoral fellow in Harvard Medical School for nearly seven years since 2002.
The Board of Directors of EssexBio is confident that the addition of Dr. Xue Qi as its CSO will strengthen the Group’s ability in drug discovery and broaden the capability of translational and therapeutics research in its current R&D centre in the PRC.
This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.